Monday 01 December 2025
Internal Reference Number: FOI_8943
Date Request Received: 06/10/2025 00:00:00
Date Request Replied To: 21/10/2025 00:00:00
This response was sent via: By Email
Request Summary: Oncology Breast Cancer
Request Category: Researcher
| Question Number 1: I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel • Atezolizumab • Capivasertib • Capecitabine as a single agent • Carboplatin + Paclitaxel • Elacestrant • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Palbociclib + Fulvestrant • Parp Inhibitors (Olaparib/Talazoparib) • Pembrolizumab Monotherapy • Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide • Carboplatin + Paclitaxel + Pembrolizumab • Pertuzumab (Perteja) + Trastuzumab (Herceptin) • Phesgo (Pertuzumab + Trastuzumab in a single injection) • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Trastuzumab deruxtecan (Enhertu) • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel • Trastuzumab emtansine (Kadcyla) • Any other active systemic anti-cancer therapy | |
| Answer To Question 1: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 33 • Abemaciclib + Fulvestrant <5 • Alpelisib + Fulvestrant 0 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide <5 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel 0 • Atezolizumab 0 • Capivasertib 0 • Capecitabine as a single agent 7 • Carboplatin + Paclitaxel <5 • Elacestrant <5 • Eribulin as a single agent or in combination <5 • Everolimus + Exemestane <5 • Fulvestrant as a single agent <5 • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 29 • Palbociclib + Fulvestrant <5 • Parp Inhibitors (Olaparib/Talazoparib) <5 • Pembrolizumab Monotherapy <5 • Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide <5 • Carboplatin + Paclitaxel + Pembrolizumab <5 • Pertuzumab (Perteja) + Trastuzumab (Herceptin) <5 • Phesgo (Pertuzumab + Trastuzumab in a single injection) 23 • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 21 • Ribociclib + Fulvestrant <5 • Sacituzumab Govitecan <5 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 6 • Trastuzumab deruxtecan (Enhertu) 6 • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel 13 • Trastuzumab emtansine (Kadcyla) <5 • Any other active systemic anti-cancer therapy 17 | |
| Question Number 2: See attached | |
| Answer To Question 2: Please see attached. To accompany this answer to question 2 please also see the documents listed below:  FOI 8943 Q2 response sheet.pdf | |
| Question Number 3: Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part. | |
| Answer To Question 3: The Trust currently do not have any clinical trials for breast cancer that are open to recruitment. However, we have participated in a number of trials that are now closed to recruitment, such as: CANDO 3, HERA, AZURE, FAST-Forward, OPTIMA, POSH, TACT, TACT 2 and many others. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
